INT 2108
Alternative Names: INT-2108Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Interius BioTherapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 07 Jan 2025 Early research in Unspecified in USA (IV) prior to January 2025 (Interius BioTherapeutics pipeline, January 2025)